VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Trial Timeline
Jul 11, 2025 → Jul 4, 2026
NCT ID
NCT07074327About VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE is a phase 1 stage product being developed by Vertex Pharmaceuticals for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The current trial status is active. This product is registered under clinical trial identifier NCT07074327. Target conditions include Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07074327 | Phase 1 | Active |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 52 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 33 |
| Placebo + Everolimus | Novartis | Approved | 85 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 77 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 51 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| Tesevatinib | Sanofi | Phase 1/2 | 40 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 51 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 64 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 74 |
| Lanreotide + saline | Ipsen | Phase 3 | 74 |
| KB105 | Krystal Biotech | Phase 2 | 49 |
| KB105 | Krystal Biotech | Phase 1/2 | 38 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 72 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 47 |
| QR-1123 | ProQR | Phase 1/2 | 33 |